## William G Haynes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7662096/publications.pdf

Version: 2024-02-01

		23567	24982
161	12,585	58	109
papers	citations	h-index	g-index
163	163	163	11069
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. Diabetologia, 2021, 64, 2773-2778.	6.3	7
2	SUMO-specific protease 2 mediates leptin-induced fatty acid oxidation in skeletal muscle. Metabolism: Clinical and Experimental, 2019, 95, 27-35.	3.4	20
3	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	6.5	140
4	Modeling human pancreatic beta cell dedifferentiation. Molecular Metabolism, 2018, 10, 74-86.	6.5	65
5	Hemoglobin A1c and C-reactive protein are independently associated with blunted nocturnal blood pressure dipping in obesity-related prediabetes. Hypertension Research, 2018, 41, 33-38.	2.7	9
6	Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model. Scientific Reports, 2017, 7, 14620.	3.3	205
7	Higher augmentation index is associated with tensionâ€type headache and migraine in middleâ€aged/older humans with obesity. Obesity, 2016, 24, 865-870.	3.0	7
8	Finger volume pulse waveforms facilitate reliable assessment of heart rate variability, but not blood pressure variability or baroreflex function. BMC Cardiovascular Disorders, 2014, 14, 180.	1.7	11
9	Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: Safety, walking distance and endothelial function. Vascular Medicine, 2014, 19, 9-17.	1.5	37
10	Effects of antipsychotic drugs on cardiovascular variability in participants with bipolar disorder. Human Psychopharmacology, 2014, 29, 145-151.	1.5	17
11	Body Fat Indices and Biomarkers of Inflammation: A Cross-Sectional Study with Implications for Obesity and Peri-implant Oral Health. International Journal of Oral and Maxillofacial Implants, 2014, 29, 1429-1434.	1.4	21
12	Association of Anxiety With Resistance Vessel Dysfunction in Human Atherosclerosis. Psychosomatic Medicine, 2013, 75, 537-544.	2.0	22
13	White matter fractional anisotropy is inversely related to anxious symptoms in older adults with atherosclerosis. International Journal of Geriatric Psychiatry, 2013, 28, 1069-1076.	2.7	10
14	Sildenafil Increases Sympathetically Mediated Vascular Tone in Humans. American Journal of Hypertension, 2013, 26, 762-769.	2.0	13
15	Acute myocardial infarctions, strokes and influenza: seasonal and pandemic effects. Epidemiology and Infection, 2013, 141, 735-744.	2.1	37
16	Screening, Diagnosis, and Treatment of Dyslipidemia Among Persons With Persistent Mental Illness: A Literature Review. Psychiatric Services, 2012, 63, 693-701.	2.0	16
17	Vasculopathy Related to Manic/Hypomanic Symptom Burden and First-Generation Antipsychotics in a Sub-Sample from the Collaborative Depression Study. Psychotherapy and Psychosomatics, 2012, 81, 235-243.	8.8	53
18	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Current Psychiatry Reviews, 2012, 8, 25-36.	0.9	63

#	Article	IF	CITATIONS
19	Rate of Weight Gain and Cardiometabolic Abnormalities in Children andÂAdolescents. Journal of Pediatrics, 2012, 161, 1010-1015.e1.	1.8	21
20	Evidence for accelerated vascular aging in bipolar disorder. Journal of Psychosomatic Research, 2012, 73, 175-179.	2.6	51
21	Vascular function is not impaired early in the course of bipolar disorder. Journal of Psychosomatic Research, 2012, 72, 195-198.	2.6	20
22	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertension Research, 2012, 35, 4-16.	2.7	159
23	Membranous Nephropathy With Renal Salt Wasting: Role of Neurohumoral Factors in Sodium Retention. American Journal of Kidney Diseases, 2012, 60, 444-448.	1.9	2
24	Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clinical Nephrology, 2012, 78, 1-9.	0.7	25
25	Gender differences in neuropsychological performance in individuals with atherosclerosis: Impact of vascular function. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 9-16.	1.3	2
26	Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. Pharmacotherapy, 2011, 31, 806-812.	2.6	12
27	Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa?. Current Psychiatry, 2010, 9, 17-A.	1.7	3
28	Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity. Journal of Neuroscience, 2009, 29, 5916-5925.	3.6	144
29	Hypothalamic ERK Mediates the Anorectic and Thermogenic Sympathetic Effects of Leptin. Diabetes, 2009, 58, 536-542.	0.6	169
30	Dissociation Between Sympathetic Nerve Traffic and Sympathetically Mediated Vascular Tone in Normotensive Human Obesity. Hypertension, 2008, 52, 687-695.	2.7	39
31	Elevated Prevalence of Obesity, Metabolic Syndrome, and Cardiovascular Risk Factors in Bipolar Disorder. Annals of Clinical Psychiatry, 2008, 20, 131-137.	0.6	165
32	Vascular smooth muscle function is associated with initiation and processing speed in patients with atherosclerotic vascular disease. Journal of the International Neuropsychological Society, 2008, 14, 535-541.	1.8	12
33	LDL Cholesteryl Oleate. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1228-1230.	2.4	3
34	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 3228-3234.	0.7	47
35	Impairments in microvascular reactivity are related to organ failure in human sepsis. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1065-H1071.	3.2	228
36	Neuropsychological Performance Is Associated With Vascular Function in Patients With Atherosclerotic Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 141-146.	2.4	26

3

#	Article	IF	CITATIONS
37	Does Cuff Location for FMD Matter in Smokers?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, .	2.4	0
38	What Is the Most Appropriate Methodology for Detection of Conduit Artery Endothelial Dysfunction?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1172-1176.	2.4	31
39	Predictors of Subjective Cognitive Difficulties in Older Adults With Atherosclerotic Vascular Disease. American Journal of Geriatric Psychiatry, 2007, 15, 328-334.	1.2	10
40	NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity, 2007, 15, 2027-2042.	3.0	32
41	Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction. Journal of Diabetes and Its Complications, 2007, 21, 149-157.	2.3	53
42	Arterial compliance and endothelial function. Current Diabetes Reports, 2007, 7, 269-275.	4.2	30
43	Role of PI3 kinase in mediating renal sympathoactivation to leptin in obesity. FASEB Journal, 2007, 21, A1193.	0.5	0
44	The selectivity of leptin resistance depends on the severity of dietâ€induced obesity in normotensive and borderline hypertensive mice. FASEB Journal, 2007, 21, A459.	0.5	0
45	Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, 1702-1709.	1.0	44
46	Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans. International Journal of Cardiology, 2006, 109, 201-206.	1.7	63
47	Homocysteine: Role and implications in atherosclerosis. Current Atherosclerosis Reports, 2006, 8, 100-106.	4.8	129
48	Antecedent Hypoglycemia, Catecholamine Depletion, and Subsequent Sympathetic Neural Responses. Endocrinology, 2006, 147, 2781-2788.	2.8	35
49	A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2183-2185.	2.4	42
50	Role of leptin in obesityâ€related hypertension. Experimental Physiology, 2005, 90, 683-688.	2.0	97
51	Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats. European Journal of Pharmacology, 2005, 518, 175-181.	3.5	12
52	Effect of hyperhomocysteinemia induced by methionine administration on flow-mediated dilatation of the brachial artery in healthy subjects. American Journal of Cardiology, 2005, 95, 428-430.	1.6	10
53	A prospective study of the effect of haemorrhoidectomy on sphincter function and faecal continence. British Journal of Surgery, 2005, 69, 396-398.	0.3	113
54	Sibutramine and the sympathetic nervous system in obese humans. Clinical Autonomic Research, 2005, 15, 189-192.	2.5	6

#	Article	IF	CITATIONS
55	Endothelial effects of leptin: Implications in health and diseases. Current Diabetes Reports, 2005, 5, 260-266.	4.2	46
56	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opinion on Emerging Drugs, 2005, 10, 643-660.	2.4	5
57	Role of Selective Leptin Resistance in Diet-Induced Obesity Hypertension. Diabetes, 2005, 54, 2012-2018.	0.6	289
58	Obesity-Associated Hypertension. Hypertension, 2005, 45, 9-14.	2.7	688
59	Dietary and Medical Therapy of Obesity. Surgical Clinics of North America, 2005, 85, 703-723.	1.5	4
60	Obesity does not increase sympathetic vascular tone in hypertensives. American Journal of Hypertension, 2005, 18, A195-A196.	2.0	1
61	Blood Vessel Function and Cognition in Elderly Patients With Atherosclerosis. Stroke, 2004, 35, e369-72.	2.0	32
62	Loss of Leptin Actions in Obesity: Two Concepts with Cardiovascular Implications. Clinical and Experimental Hypertension, 2004, 26, 629-636.	1.3	30
63	Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. American Journal of Cardiology, 2004, 93, 664-668.	1.6	22
64	Obesity-related hypertension: Is there a role for selective leptin resistance?. Current Hypertension Reports, 2004, 6, 230-235.	3.5	38
65	Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism: Clinical and Experimental, 2004, 53, 1454-1461.	3.4	62
66	Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E891-E895.	3.5	103
67	Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. Journal of Clinical Investigation, 2004, 114, 652-658.	8.2	162
68	Leptin and the Cardiovascular System. Endocrine Reviews, 2004, 59, 225-244.	6.7	98
69	Homocysteine: is it a clinically important cardiovascular risk factor?. Cleveland Clinic Journal of Medicine, 2004, 71, 729-734.	1.3	91
70	Leptin Signaling in the Central Nervous System. , 2004, , 86-VI.		1
71	A leptin-sympathetic-leptin feedback loop: potential implications for regulation of arterial pressure and body fat. Acta Physiologica Scandinavica, 2003, 177, 345-349.	2.2	55
72	Leptin administration to normal rats does not alter catecholamine responsiveness to insulin-induced hypoglycemia. Metabolism: Clinical and Experimental, 2003, 52, 1484-1490.	3.4	3

#	Article	IF	Citations
73	Intracellular Mechanisms Involved in Leptin Regulation of Sympathetic Outflow. Hypertension, 2003, 41, 763-767.	2.7	97
74	Triglyceride-Rich Lipoproteins and Vascular Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 153-155.	2.4	17
75	Periodontal Disease and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1309-1311.	2.4	68
76	Xanthine Oxidase Inhibition Reverses Endothelial Dysfunction in Heavy Smokers. Circulation, 2003, 107, 416-421.	1.6	214
77	Leptin and Body Fat in Type 2 Diabetes and Monodrug Therapy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1543-1553.	3.6	40
78	Role of Melanocortin-4 Receptors in Mediating Renal Sympathoactivation to Leptin and Insulin. Journal of Neuroscience, 2003, 23, 5998-6004.	3.6	169
79	Selective Resistance to Central Neural Administration of Leptin in Agouti Obese Mice. Hypertension, 2002, 39, 486-490.	2.7	114
80	The Concept of Selective Leptin Resistance: Evidence From Agouti Yellow Obese Mice. Diabetes, 2002, 51, 439-442.	0.6	202
81	Leptin Potentiates Thermogenic Sympathetic Responses to Hypothermia: A Receptor-Mediated Effect. Diabetes, 2002, 51, 2434-2440.	0.6	50
82	Acute Neuropsychological Functioning Following Cardiosurgical Interventions Associated With the Production of Intraoperative Cerebral Microemboli. Clinical Neuropsychologist, 2002, 16, 463-471.	2.3	26
83	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1064-1064.	2.4	2
84	Role of endothelin in cardiovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 1-15.	1.7	158
85	Pharmacotherapy of obesity: lessons from clinical trials in hypertension. Journal of Hypertension, 2002, 20, 1731-1735.	0.5	3
86	Impaired skeletal muscle and skin microcirculatory function in human obesity. Journal of Hypertension, 2002, 20, 1401-1405.	0.5	38
87	Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. Journal of Hypertension, 2002, 20, 1245-1250.	0.5	178
88	Differential modulation of leptin-induced sympathoexcitation by baroreflex activation. Journal of Hypertension, 2002, 20, 1633-1641.	0.5	39
89	Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. Clinical Science, 2002, 103, 53S-58S.	4.3	13
90	Effect of hyperhomocysteinemia on protein C activation and activity. Blood, 2002, 100, 2108-2112.	1.4	36

#	Article	IF	Citations
91	Hemodynamic consequences of neuropeptide Y-induced obesity. American Journal of Hypertension, 2002, 15, 137-142.	2.0	15
92	α <sub>2</sub> -Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2606-H2611.	3.2	14
93	Cardiovascular and sympathetic effects of leptin. Current Hypertension Reports, 2002, 4, 119-125.	3.5	50
94	Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovascular Drugs and Therapy, 2002, 16, 391-399.	2.6	74
95	Leptin and the central neural mechanisms of obesity hypertension. Drugs of Today, 2002, 38, 807.	2.4	21
96	Does leptin cause functional peripheral sympatholysis?. American Journal of Hypertension, 2001, 14, 615-618.	2.0	21
97	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clinical Science, 2001, 100, 161-167.	4.3	166
98	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clinical Science, 2001, 100, 161.	4.3	70
99	Unilateral vs. bilateral ultrasound in the monitoring of cerebral microemboli. Ultrasound in Medicine and Biology, 2001, 27, 757-760.	1.5	4
100	Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. BioEssays, 2001, 23, 1095-1099.	2.5	42
101	Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. American Journal of Cardiology, 2001, 88, 285-290.	1.6	43
102	Role of Corticotrophin-Releasing Factor in Effects of Leptin on Sympathetic Nerve Activity and Arterial Pressure. Hypertension, 2001, 38, 384-388.	2.7	59
103	Leptin Acts in the Central Nervous System to Produce Dose-Dependent Changes in Arterial Pressure. Hypertension, 2001, 37, 936-942.	2.7	138
104	Reduced venous responsiveness to endothelinâ€1 but not noradrenaline in hypertensive chronic renal failure. Nephrology Dialysis Transplantation, 2001, 16, 295-301.	0.7	10
105	Does Leptin Stimulate Nitric Oxide to Oppose the Effects of Sympathetic Activation?. Hypertension, 2001, 38, 1081-1086.	2.7	61
106	Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 2000, 98, 65-70.	4.3	15
107	Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 2000, 98, 65.	4.3	12
108	Resistance vessel endothelial function in healthy humans during transient postprandial hypertriglyceridemia. American Journal of Cardiology, 2000, 85, 381-385.	1.6	47

#	Article	IF	CITATIONS
109	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. Clinical Pharmacology and Therapeutics, 2000, 68, 67-74.	4.7	1
110	Interaction between leptin and sympathetic nervous system in hypertension. Current Hypertension Reports, 2000, 2, 311-318.	3.5	105
111	Endothelin receptor antagonism in patients with chronic heart failure. Cardiovascular Research, 2000, 47, 166-172.	3.8	38
112	Impairment of Endothelium-Dependent Vasodilation of Resistance Vessels in Patients With Obstructive Sleep Apnea. Circulation, 2000, 102, 2607-2610.	1.6	634
113	Role of Oxidant Stress in Endothelial Dysfunction Produced by Experimental Hyperhomocyst(e)inemia in Humans. Circulation, 1999, 100, 1161-1168.	1.6	398
114	Obesity-Induced Hypertension. Hypertension, 1999, 33, 537-541.	2.7	171
115	Reduced endogenous endothelin-1–mediated vascular tone in chronic renal failure. Kidney International, 1999, 55, 613-620.	5.2	27
116	Interactions Between the Melanocortin System and Leptin in Control of Sympathetic Nerve Traffic. Hypertension, 1999, 33, 542-547.	2.7	349
117	Effects of obstructive sleep apnea on endothelin-1 and blood pressure. Journal of Hypertension, 1999, 17, 61-66.	0.5	394
118	Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. Journal of Hypertension, 1999, 17, 1949-1953.	0.5	221
119	The effects of short-term passive smoke exposure on endothelium-dependent and independent vasodilation. Journal of Hypertension, 1999, 17, 1395-1401.	0.5	32
120	Homocysteine as a novel risk factor for atherosclerosis. Current Opinion in Cardiology, 1999, 14, 283-291.	1.8	28
121	Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney International, 1998, 53, 1068-1077.	5.2	110
122	Nitric oxide and gallâ€bladder motor function. Alimentary Pharmacology and Therapeutics, 1998, 12, 425-432.	3.7	15
123	Plasma leptin in diabetic and insulin-treated diabetic and normal rats. Metabolism: Clinical and Experimental, 1998, 47, 584-591.	3.4	61
124	Bosentan in Essential Hypertension. New England Journal of Medicine, 1998, 339, 346-347.	27.0	15
125	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. Circulation, 1998, 97, 2323-2330.	1.6	158
126	Endothelin as a regulator of cardiovascular function in health and disease. Journal of Hypertension, 1998, 16, 1081-1098.	0.5	320

#	Article	IF	CITATIONS
127	Frequency response characteristics of sympathetically mediated vasomotor waves in humans. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1277-H1283.	3.2	62
128	The Endothelins. Principles of Medical Biology, 1997, 10, 543-572.	0.1	0
129	Sympathetic and Cardiorenal Actions of Leptin. Hypertension, 1997, 30, 619-623.	2.7	276
130	Effects of Leptin on Insulin Sensitivity in Normal Rats. Endocrinology, 1997, 138, 3395-3401.	2.8	77
131	The increase in human plasma immunoreactive endothelin but not big endothelinâ€1 or its Câ€terminal fragment induced by systemic administration of the endothelin antagonist TAKâ€044. British Journal of Pharmacology, 1996, 119, 311-314.	5.4	62
132	Endothelin production in sepsis and the adult respiratory distress syndrome. Intensive Care Medicine, 1996, 22, 52-56.	8.2	61
133	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. Circulation, 1996, 93, 1860-1870.	1.6	257
134	Vasodilator Effects of Endothelin-Converting Enzyme Inhibition and Endothelin ET A Receptor Blockade in Chronic Heart Failure Patients Treated With ACE Inhibitors. Circulation, 1996, 94, 2131-2137.	1.6	148
135	Genetic Characterization of the â€~New' Harlan Sprague Dawley Dahl Salt-Sensitive Rats. Hypertension, 1996, 27, 546-551.	2.7	16
136	Does nitric oxide synthesis really contribute to systemic blood pressure control?. Journal of Hypertension, 1995, 13, 709.	0.5	1
137	Measurement of C-Terminal Fragment of Big Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S34-36.	1.9	11
138	Endothelins as Regulators of Vascular Tone in Man. Clinical Science, 1995, 88, 509-517.	4.3	49
139	The Role of Endothelin-1 in Cardiovascular Physiology and Pathophysiology. Scottish Medical Journal, 1995, 40, 69-71.	1.3	6
140	Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney International, 1995, 48, 806-813.	5.2	72
141	Phosphoramidon inhibition of the <i>in vivo</i> conversion of big endothelinâ€1 to endothelinâ€1 in the human forearm. British Journal of Pharmacology, 1995, 116, 1821-1828.	5.4	47
142	Forearm Vasoconstriction to Endothelin-1 Is Mediated by ETA and ETB Receptors In Vivo in Humans. Journal of Cardiovascular Pharmacology, 1995, 26, S40-43.	1.9	1
143	Endothelium-Dependent Modulation of Venoconstriction to Sarafotoxin S6c in Human Veins In Vivo. Journal of Cardiovascular Pharmacology, 1995, 26, S180-182.	1.9	13
144	Physiologic Role of Endothelin in Maintenance of Vascular Tone in Humans. Journal of Cardiovascular Pharmacology, 1995, 26, S183-185.	1.9	3

#	Article	IF	CITATIONS
145	Endothelin ET <sub>A</sub> and ET <sub>B</sub> Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation, 1995, 92, 357-363.	1.6	229
146	Measurement of C-Terminal Fragment of Big Endothelin-1. Journal of Cardiovascular Pharmacology, 1995, 26, S34-36.	1.9	1
147	Plasma endothelin following cardiac arrest: differences between survivors and non-survivors. Resuscitation, 1994, 27, 117-122.	3.0	22
148	Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, The, 1994, 344, 852-854.	13.7	577
149	Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. British Journal of Clinical Pharmacology, 1993, 36, 293-301.	2.4	3
150	Flosequinan in heart failure. Lancet, The, 1993, 341, 1100-1101.	13.7	1
151	L-NMMA Increases blood pressure in man. Lancet, The, 1993, 342, 931-932.	13.7	58
152	Endothelins come of age. Lancet, The, 1993, 342, 1439-1440.	13.7	20
153	Endothelium-Dependent Modulation of Responses to Endothelin-1 in Human Veins. Clinical Science, 1993, 84, 427-433.	4.3	59
154	The Endothelin Family of Peptides: Local Hormones with Diverse Roles in Health and Disease?. Clinical Science, 1993, 84, 485-500.	4.3	213
155	Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. Journal of Hypertension, 1993, 11, 1375-1380.	0.5	243
156	Venoconstriction to Endothelin-1 in Humans Is Attenuated by Local Generation of Prostacyclin But Not Nitric Oxide. Journal of Cardiovascular Pharmacology, 1993, 22, S317-S320.	1.9	12
157	Endothelin-1 and Aggregation of Human Platelets In Vitro. Journal of Cardiovascular Pharmacology, 1993, 22, S204-S206.	1.9	7
158	The potassium channel opener BRL 38227 inhibits binding of [1251]-labelled endothelin-1 to rat cardiac membranes. Biochemical and Biophysical Research Communications, 1992, 185, 630-635.	2.1	13
159	Nitric oxide in liver failure. Lancet, The, 1991, 338, 1590.	13.7	38
160	Increase in skin microcirculatory blood flow after local renin inhibition in man. Journal of Hypertension, 1991, 9, S230.	0.5	1
161	Anoâ€rectal activity in man during rectal infusion of saline: a dynamic assessment of the anal continence mechanism Journal of Physiology, 1982, 330, 45-56.	2.9	66